Loading
A Seattle trial in 11 people with advanced melanoma that gave cyclophosphamide before their own melanoma-targeting T cells, followed by the immune signal IL-2. It ran from 2006 to 2012.
The registry describes a phase I study of autologous CD8+ antigen-specific T-cell clones following cyclophosphamide conditioning, with aldesleukin, in metastatic melanoma, started in December 2006, with primary completion in January 2011, completion in February 2012 and an actual enrolment of 11 (ClinicalTrials.gov NCT00438984). Cassian Yee is listed as principal investigator; the record names NIH grant R21CA128283 (ClinicalTrials.gov NCT00438984). No results are posted.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/